射频消融后联合伊立替康与卡培他滨化疗在结肠癌伴肝转移治疗中的价值分析

Value of radiofrequency ablation combined with irinotecan and capecitabine chemotherapy in treatment of colon cancer patients with liver metastasis

目的观察在结肠癌伴肝转移患者中,应用射频消融联合伊立替康与卡培他滨化疗的方案的临床价值.方法回顾性分析2011-07/2016-07期间,嵊州市人民医院收治的150例结肠癌伴肝转移的临床资料,所选患者均行射频消融治疗,根据射频消融后的化疗方案不同分为两组,其中70例患者给予伊立替康联合氟尿嘧啶方案进行治疗,将其作为对照组,80例患者给予伊立替康联合卡培他滨方案进行治疗,将其作为观察组.然后将两组患者的临床疗效、不良反应等指标进行比较.结果经过治疗后,观察组患者的治疗总有效率为71.25%,高于对照组的64.28%,差异无统计学意义(P>0.05);观察组患者的无进展生存时间、总生存时间分别为5.3±0.8、15.1±1.9,高于对照组的4.6±0.5、12.5±1.7,差异无统计学意义(P>0.05);两组患者在脱发、肝功能损害、血小板减少的发生率上无明显差异,无统计学意义(P>0.05);观察组患者的腹泻发生率为41.43%,明显高于对照组的13.75%,差异具有统计学意义(P<0.05);观察组患者恶心、呕吐发生率、白细胞减少发生率及贫血发生率均低于对照组(12.5%、10.00%、16.25%vs 44.29%、38.57%、42.86%),差异有统计学意义(P<0.05).结论在结肠癌伴肝转移患者中应用射频消融联合伊立替康与卡培他滨化疗的治疗方案,在保证临床疗效的同时,且具有较高的用药安全性.

AIM To assess the clinical value of radiofrequency ablation combined with irinotecan and capecitabine chemotherapyin colon cancer patients with liver metastasis METHODS The clinical data of 150 colon cancer patients with liver metastasis who were admitted to People＇s Hospital of Shengzhou from July 2011 to July 2016 were retrospectively analyzed. All patients underwent radiofrequency ablation therapy and, based on the chemotherapy protocol used after radiofrequency ablation, they were divided into two groups： 70 patients treated with the irinotecan and fluorouracil regimen （control group）, and 80 patients treated with the irinotecan and capecitabine regimen （observation group）. Then two groups of patients were compared in clinical efficacy, adverse reactions, and other indicators. RESULTS The total effective rate of the observation group was 71.25%, which was higher than that of the control group （64.28%）, but the difference was not statistically significant （P 〉 0.05）. The progression free survival and overall survival of patients in the observation group were 5.3 ± 0.8 and 15.1 ± 1.9, respectively, which were higher than those of the control group （4.6 ± 0.5 and 12.5 ±1.7, respectively）, but the difference was not statistically significant （P 〉 0.05）. There was no significant difference between the two groups in the incidence of hair loss, liver damage, or thrombocytopenia （P 〉 0.05）. The incidence of diarrhea in the observation group was significantly higher than that of the control group （41.43% vs 13.75%, P 〈 0.05）. The incidence rates of nausea, vomiting, leukopenia, and anemia in the observation group were significantly lower than those of the control group （12.5% vs 44.29%, 10.00% vs 38.57%, 16.25% vs 42.86%, respectively; P 〈 0.05）.The application of radiofrequency ablation combined with irinotecan and capecitabine chemotherapy in colon cancer patients with liver metastasis can ensure clinical efficacy and is associated with higher medication safety.